Serafim, Rodolfo Bortolozo; Cardoso, Cibele; Arfelli, Vanessa Cristina; Valente, Valeria; Archangelo, Leticia Fröhlich 
Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. Unidade: FMRP
Subjects: ANTINEOPLÁSICOS, LINHAGEM CELULAR, DANO AO DNA, GLIOMA, FARMACOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SERAFIM, Rodolfo Bortolozo et al. PIMREG expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, v. 1868, p. 166382, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.bbadis.2022.166382. Acesso em: 19 nov. 2024.APA
Serafim, R. B., Cardoso, C., Arfelli, V. C., Valente, V., & Archangelo, L. F. (2022). PIMREG expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1868, 166382. doi:10.1016/j.bbadis.2022.166382NLM
Serafim RB, Cardoso C, Arfelli VC, Valente V, Archangelo LF. PIMREG expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response [Internet]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2022 ; 1868 166382.[citado 2024 nov. 19 ] Available from: https://doi.org/10.1016/j.bbadis.2022.166382Vancouver
Serafim RB, Cardoso C, Arfelli VC, Valente V, Archangelo LF. PIMREG expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response [Internet]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2022 ; 1868 166382.[citado 2024 nov. 19 ] Available from: https://doi.org/10.1016/j.bbadis.2022.166382
